Breast cancer prognostic classification in the molecular era: the role of histological grade.

PubWeight™: 2.33‹?› | Rank: Top 2%

🔗 View Article (PMC 2949637)

Published in Breast Cancer Res on July 30, 2010

Authors

Emad A Rakha1, Jorge S Reis-Filho, Frederick Baehner, David J Dabbs, Thomas Decker, Vincenzo Eusebi, Stephen B Fox, Shu Ichihara, Jocelyne Jacquemier, Sunil R Lakhani, José Palacios, Andrea L Richardson, Stuart J Schnitt, Fernando C Schmitt, Puay-Hoon Tan, Gary M Tse, Sunil Badve, Ian O Ellis

Author Affiliations

1: Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK.

Articles citing this

Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38

Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99

The molecular pathology of breast cancer progression. J Pathol (2010) 1.65

A new genome-driven integrated classification of breast cancer and its implications. EMBO J (2013) 1.47

Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst (2011) 1.45

Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res (2011) 1.36

Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol (2012) 1.32

Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res (2011) 1.30

Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat (2013) 1.26

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer (2011) 1.15

The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS One (2012) 1.08

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. Geburtshilfe Frauenheilkd (2013) 1.08

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2012) 1.05

Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol (2011) 1.02

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer (2014) 1.01

Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res (2012) 0.96

Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis. Br J Cancer (2014) 0.94

Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers. Breast Cancer Res (2013) 0.92

Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. Int J Breast Cancer (2012) 0.92

Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis. BMC Cancer (2012) 0.91

Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg (2012) 0.90

Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition. PLoS One (2014) 0.90

Taxane benefit in breast cancer--a role for grade and chromosomal stability. Nat Rev Clin Oncol (2013) 0.89

Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. J Pathol (2016) 0.86

The genomic map of breast cancer: which roads lead to better targeted therapies? Breast Cancer Res (2013) 0.86

Disease-on-a-chip: mimicry of tumor growth in mammary ducts. Lab Chip (2013) 0.83

Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer. Eur Radiol (2015) 0.83

Therapeutic targeting of casein kinase 1δ in breast cancer. Sci Transl Med (2015) 0.83

LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer. Breast Cancer Res Treat (2015) 0.83

Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma. PLoS One (2012) 0.83

Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population. World J Surg Oncol (2012) 0.82

Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. Am J Pathol (2014) 0.82

Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes. Histopathology (2014) 0.81

Assessment of Functional Differences in Malignant and Benign Breast Lesions and Improvement of Diagnostic Accuracy by Using US-guided Diffuse Optical Tomography in Conjunction with Conventional US. Radiology (2016) 0.81

Semi-automated evaluation of Ki-67 index in invasive ductal carcinoma of the breast. Oncol Lett (2013) 0.81

Molecular classification of breast cancer. Virchows Arch (2014) 0.80

A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. PLoS One (2013) 0.80

New breast cancer prognostic factors identified by computer-aided image analysis of HE stained histopathology images. Sci Rep (2015) 0.80

MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. Oncotarget (2016) 0.80

A ranking-based meta-analysis reveals let-7 family as a meta-signature for grade classification in breast cancer. PLoS One (2015) 0.79

Histopathological and genomic grading provide complementary prognostic information in breast cancer: a study on publicly available datasets. Patholog Res Int (2011) 0.79

Computational prognostic indicators for breast cancer. Cancer Manag Res (2014) 0.79

A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling. Oncotarget (2014) 0.79

Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PLoS One (2014) 0.79

The biology of malignant breast tumors has an impact on the presentation in ultrasound: an analysis of 315 cases. BMC Womens Health (2013) 0.79

A microscopic landscape of the invasive breast cancer genome. Sci Rep (2016) 0.79

Clinical and Biological Significance of Cathepsin D Levels in Breast Cancer Cytosol in Women Over 70 years. Biomark Cancer (2012) 0.79

Application of imaging mass spectrometry for the molecular diagnosis of human breast tumors. Sci Rep (2016) 0.79

An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer. Breast Cancer Res (2014) 0.79

Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res (2015) 0.78

Genome and transcriptome delineation of two major oncogenic pathways governing invasive ductal breast cancer development. Oncotarget (2015) 0.77

Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression. World J Surg Oncol (2014) 0.77

Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study. PLoS One (2013) 0.77

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. BMC Cancer (2015) 0.77

Computer-aided assessment of tumor grade for breast cancer in ultrasound images. Comput Math Methods Med (2015) 0.77

The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression. BMC Cancer (2013) 0.76

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. Oncol Lett (2014) 0.76

Genomic approaches in breast cancer research. Brief Funct Genomics (2013) 0.76

Breast cancer survival disparity between African American and Caucasian women in Arkansas: A race-by-grade analysis. Oncol Lett (2016) 0.75

Determining breast cancer histological grade from RNA-sequencing data. Breast Cancer Res (2016) 0.75

No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev (2016) 0.75

Metabolic syndrome and pre-diabetes contribute to racial disparities in breast cancer outcomes: hypothesis and proposed pathways. Diabetes Metab Res Rev (2016) 0.75

Serum Oxidative Stress Markers and Genotoxic Profile Induced by Chemotherapy in Patients with Breast Cancer: A Pilot Study. Oxid Med Cell Longev (2015) 0.75

Differential immune cell densities in ductal carcinoma In-Situ and invasive breast cancer: Possible role of leukocytes in early stages of carcinogenesis. Pak J Med Sci (2015) 0.75

Breast Cancer by Age at Diagnosis in the Gharbiah, Egypt, Population-Based Registry Compared to the United States Surveillance, Epidemiology, and End Results Program, 2004-2008. Biomed Res Int (2015) 0.75

Gene expression analysis supports tumor threshold over 2.0 cm for T-category breast cancer. EURASIP J Bioinform Syst Biol (2016) 0.75

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. Br J Cancer (2014) 0.75

Improving the Prognostic Ability through Better Use of Standard Clinical Data - The Nottingham Prognostic Index as an Example. PLoS One (2016) 0.75

Additional Value of Diffusion-Weighted Imaging to Evaluate Prognostic Factors of Breast Cancer: Correlation with the Apparent Diffusion Coefficient. Iran J Radiol (2016) 0.75

Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. Ann Oncol (2016) 0.75

DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms. Breast Cancer Res (2017) 0.75

Model predictions for the wide-angle x-ray scatter signals of healthy and malignant breast duct biopsies. J Med Imaging (Bellingham) (2015) 0.75

MUCI positive cutaneous metastasis with transepidermal elimination from a breast carcinoma. Int Med Case Rep J (2013) 0.75

Racial disparities in survival and age-related outcome in postsurgery breast cancer patients in a new york city community hospital. ISRN Oncol (2014) 0.75

Identifying grade/stage-related active modules in human co-regulatory networks: a case study for breast cancer. OMICS (2012) 0.75

Improving your four-dimensional image: traveling through a decade of light-sheet-based fluorescence microscopy research. Nat Protoc (2017) 0.75

Clinicopathologic subtypes and compromise of lymph nodes in patients with breast cancer. Ecancermedicalscience (2014) 0.75

Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. Biomark Insights (2016) 0.75

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2016) 0.75

The prognostic significance of protein tyrosine phosphatase 4A2 in breast cancer. Onco Targets Ther (2015) 0.75

Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J Breast Health (2013) (2015) 0.75

Rapid staining and imaging of subnuclear features to differentiate between malignant and benign breast tissues at a point-of-care setting. J Cancer Res Clin Oncol (2016) 0.75

Recent perspectives of breast cancer prognosis and predictive factors. Oncol Lett (2016) 0.75

Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature. Breast Cancer (Dove Med Press) (2011) 0.75

Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. BMC Cancer (2015) 0.75

Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Mod Pathol (2016) 0.75

Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol (2017) 0.75

New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. PLoS One (2017) 0.75

Expression of Krüppel-like factor 4 in breast cancer tissues and its effects on the proliferation of breast cancer MDA-MB-231 cells. Exp Ther Med (2017) 0.75

Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer. Int J Mol Sci (2017) 0.75

Overexpression of cofilin correlates with poor survival in breast cancer: A tissue microarray analysis. Oncol Lett (2017) 0.75

Articles cited by this

A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02

Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60

Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50

Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63

Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51

The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat (1992) 6.51

Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol (2007) 3.55

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer (2005) 3.07

Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol (1995) 2.63

Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37

The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol (2010) 2.23

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol (2009) 2.17

Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol (2008) 2.13

"Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer (2004) 1.88

Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol (1995) 1.84

Reading the prognosis of the individual with breast cancer. Eur J Cancer (2007) 1.83

Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest (2008) 1.80

Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg (2002) 1.79

Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol (2009) 1.77

Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer (2007) 1.70

The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat (1994) 1.69

Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat (1999) 1.62

The assessment of histological differentiation in breast cancer. Aust N Z J Surg (1984) 1.62

Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst (2007) 1.52

Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer (1991) 1.49

Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer (2007) 1.46

Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol (2006) 1.45

Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. Cancer (2004) 1.42

Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol (2000) 1.42

Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer (1989) 1.41

Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat (2007) 1.39

The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer (2000) 1.35

Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol (2001) 1.33

Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol (2006) 1.31

Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol (2001) 1.26

Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer (1986) 1.25

Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol (2001) 1.23

An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J Clin Pathol (2007) 1.23

Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol (2006) 1.22

Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology (1995) 1.17

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess (2006) 1.15

Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg (2000) 1.15

Histological grading of invasive breast carcinoma--a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology (2009) 1.06

Pathology characteristics that optimize outcome prediction of a breast screening trial. Br J Cancer (2000) 1.06

Histologic grading in breast cancer--reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol (2000) 1.04

Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer (1995) 1.03

Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer (2009) 1.02

A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res (2004) 1.01

Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol (2002) 1.01

Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol (2008) 1.01

Histological grading of breast cancer. Interobserver, reproducibility and prognostic significance. Pathol Res Pract (1990) 0.98

Observer variation in histological grading of breast cancer. Eur J Surg Oncol (1989) 0.95

The prognosis of small primary breast cancers. Eur J Cancer (1999) 0.94

Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor. J Surg Oncol (1999) 0.92

Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J Clin Pathol (2002) 0.91

ONCOPOOL - a European database for 16,944 cases of breast cancer. Eur J Cancer (2010) 0.90

Interobserver variation in breast cancer grading: a statistical modeling approach. Anal Quant Cytol Histol (2006) 0.86

Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann Oncol (2009) 0.85

Interobserver agreement of the Nottingham histologic grading scheme for infiltrating duct carcinoma breast. Indian J Cancer (2000) 0.83

Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). Eur J Cancer (2009) 0.79

[Reproducibility of histoprognostic grades of invasive breast cancer]. Ann Pathol (1998) 0.77

Articles by these authors

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89

Signatures of mutational processes in human cancer. Nature (2013) 21.63

International network of cancer genome projects. Nature (2010) 20.35

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41

Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45

Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67

Triple-negative breast cancer. N Engl J Med (2010) 11.39

The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24

Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88

The life history of 21 breast cancers. Cell (2012) 10.59

Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66

Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60

Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res (2008) 6.95

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89

Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88

MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41

CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35

Prognostic markers in triple-negative breast cancer. Cancer (2007) 6.28

Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med (2010) 6.04

Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70

Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol (2008) 5.38

JAK-STAT signaling: from interferons to cytokines. J Biol Chem (2007) 5.28

Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24

Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79

Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76

High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70

BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66

Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33

Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell (2007) 4.30

Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene (2002) 4.20

Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol (2011) 4.09

A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell (2007) 3.97

Magnetic resonance imaging of the breast prior to biopsy. JAMA (2004) 3.97

Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89

Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol (2004) 3.80

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst (2008) 3.60

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol (2007) 3.55

Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology (2006) 3.42

Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol (2006) 3.33

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27

A non-genetic route to aneuploidy in human cancers. Nat Cell Biol (2011) 3.25

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer (2005) 3.07

Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A (2010) 3.03

Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91

Integrated profiling of basal and luminal breast cancers. Cancer Res (2007) 2.86

Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res (2006) 2.86

Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat (2009) 2.85

Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77

Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res (2006) 2.73

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72

Molecular evolution of breast cancer. J Pathol (2005) 2.69

Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res (2008) 2.69

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66

Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget (2010) 2.64

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62

Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer (2010) 2.62